Here are the 10-K annual reports from Lantheus Holdings, Inc (LNTH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LNTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LNTH filings page.
Lantheus Holdings presents an in-depth annual update highlighting a major strategic shift toward radiopharmaceutical oncology and precision diagnostics. The company relies on key products PYLARIFY, DEFINITY and Neuraceq, supported by AI tools aBSI and aPROMISE and CDMO services acquired with Evergreen.
In 2025–2026, Lantheus executed significant portfolio moves, including selling its SPECT business to SHINE Technologies for consideration of up to $155.0 million, acquiring Life Molecular for $352.9 million in upfront cash plus up to $400.0 million in milestones, and buying Evergreen for $276.4 million upfront with up to $727.5 million in potential milestones.
The report notes a leadership transition with Mary Anne Heino becoming CEO on January 1, 2026, and outlines an extensive pipeline in prostate cancer and Alzheimer’s disease, including MK-6240, NAV-4694, LNTH-2501, LNTH-240x assets and PNT2003. It also summarizes numerous risks: dependence on PYLARIFY and DEFINITY, reimbursement and regulatory uncertainties, integration of acquisitions, patent and ANDA litigation around PNT2003, and competition from large global radiopharmaceutical and imaging players.